'Use ARBs to treat hypertensives with CKD'

Hypertensive patients with chronic kidney disease (CKD) may be best treated with an angiotensin receptor blocker (ARB), suggests Japanese research.

The findings come from sub-analysis of a study into the benefits of ARBs in patients with coronary artery disease (CAD).

This showed that the risk of major adverse cardiac events was reduced by 21 per cent in patients with impaired renal function.

ARBs also reduced the risk of new-onset diabetes by 63 per cent, delegates were told at the American Heart Association scientific sessions in Orlando, Florida.

For the study, over 2,000 patients with CAD were randomly assigned to treatment with the ARB candesartan or standard therapy.

In Japan this is a calcium-channel blocker or beta-blocker, followed by a diuretic. However, 71 per cent of these patients were also taking ACE inhibitor, said lead researcher Dr Hiroshi Kasanuki from Tokyo Women’s Medical University.

 The study showed that ARBs had little effect on the risk of major adverse cardiac events in these patients at four-year follow-up, reducing risk by a non-significant 11 per cent.

rachel.liddle@haymarket.com

For more details visit the Scientific Sessions 2007 website  

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Care home vaccination to begin as Scottish minister says Pfizer vaccine packs can be split up

Care home vaccination to begin as Scottish minister says Pfizer vaccine packs can be split up

Vaccination of care home residents against COVID-19 will start on 14 December in...

How will the COVID-19 vaccination programme get underway?

How will the COVID-19 vaccination programme get underway?

Following the MHRA's approval of Pfizer/BioNTech's COVID-19 jab the government has...

NHS must keep doctors who returned in pandemic as overseas supply dries up, says GMC

NHS must keep doctors who returned in pandemic as overseas supply dries up, says GMC

Doctors who rejoined the NHS workforce in the pandemic must be urged to stay to help...

GPs unlikely to begin COVID-19 vaccination for 'at least two weeks', says BMA

GPs unlikely to begin COVID-19 vaccination for 'at least two weeks', says BMA

GP practices are unlikely to receive stocks of COVID-19 vaccine 'for at least another...

JCVI confirms priority groups for COVID-19 vaccination

JCVI confirms priority groups for COVID-19 vaccination

The Joint Committee on Vaccination and Immunisation (JCVI) has published a final...

MHRA approves Pfizer/BioNTech jab paving way for COVID-19 vaccination to start

MHRA approves Pfizer/BioNTech jab paving way for COVID-19 vaccination to start

The MHRA has approved the Pfizer/BioNTech COVID-19 vaccine for use in the UK and...